GI Innovation
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GI Innovation is a South Korean biotechnology company that develops next-generation immunotherapy drugs, medicines that harness the immune system to fight cancer and allergies.
Its drug candidates target oncology and allergic disease, and its business model centers on licensing these candidates to larger pharmaceutical partners at early development stages rather than commercializing them independently. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company's core structural fact is that it operates primarily as a technology-licensing business, having completed multiple global licensing deals. Its proprietary GI-SMART™ platform is used to discover and engineer novel fusion-protein drug candidates.
Summary is AI-generated and may contain errors · figures from DART filings
The company has received clinical-stage funding support from Korea's national drug-development foundation, KDDF, across several of its pipeline programs.
GI Innovation in five facts
What does GI Innovation do?
GI Innovation is a South Korean biotechnology company that develops next-generation immunotherapy drugs, medicines that harness the immune system to fight cancer and allergies.
Where is GI Innovation listed and in which sector?
GI Innovation (Korean name: 지아이이노베이션) trades under KRX code 358570 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is GI Innovation?
Its market capitalisation was US$392.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GI Innovation's latest annual revenue and operating profit?
For fiscal year 2025, GI Innovation reported revenue of US$4.4M, an operating loss of US$30.7M and a net loss of US$26.5M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 23943.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 7
- [Amended] Material management matter relevant to investment decisionsOct 1
- Report on large shareholdings (5% rule) (standard)Sep 4
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GI Innovation reported separate results for FY2025: revenue of US$3.97M (+23943.4% year on year), an operating loss of US$27.4M and a net loss of US$23.7M.
Earnings · Feb 6 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 8